Skip to content
2000
Volume 21, Issue 1
  • ISSN: 1573-4056
  • E-ISSN: 1875-6603
file format pdf download PDF
side by side viewer icon HTML

Abstract

Purpose

MRI could be considered as a non-destructive disease diagnosis procedure, this procedure does not allow directly molecular types of cancer. Herein, we aimed to evaluate the correlation of breast MRI background parenchymal enhancement (BPE) and fibroglandular tissue (FGT) with the molecular subtypes and immunohistochemical markers of breast cancer.

Methods

This was a single-cross-sectional retrospective study.Fifty-six patients diagnosed with unilateral breast cancer who underwent breast MRI scans before needle biopsy or surgery were selected. The relationship between qualitative and quantitative BPE/FGT ratios and the expression of breast cancer molecular subtypes and immunohistochemical markers were evaluated in patients with breast cancer.

Results

Quantitative BPE (BPE%) of luminal A and luminal B was significantly lower than that of triple-negative breast cancer. There was no significant difference in the qualitative BPE/FGT between the different breast cancer subtypes. The quantitative BPE (BPE%) of estrogen receptor (ER)-negative tumors was higher than that of the ER-positive tumors, and the expression of FGT%, BPE%, and other immunohistochemical markers (human epidermal growth factor receptor-2(HER-2), progesterone receptor (PR), and Ki-67) were not significantly different. The proportion of high BPE distribution in HER-2 positive tumors was higher than that in the HER-2 negative group; however, there was no significant difference in the expression of qualitative BPE/FGT and other immunohistochemical markers (ER, PR, and Ki-67).

Conclusion

There were significant differences in the levels of BPE among the different molecular subtypes. Therefore, BPE may be a potential imaging biomarker for the diagnosis of the molecular subtypes of breast cancer.

© 2025 The Author(s).
© 2025 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cmir/10.2174/0115734056347327250117073638
2025-01-01
2025-10-25

  • From This Site

    /content/journals/cmir/10.2174/0115734056347327250117073638
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmir/21/1/CMIR-21-E15734056347327.html?itemId=/content/journals/cmir/10.2174/0115734056347327250117073638&mimeType=html&fmt=ahah

References

  1. SiegelR.L. MillerK.D. FuchsH.E. JemalA. Cancer statistics, 2021.CA Cancer J. Clin.202171173310.3322/caac.2165433433946
     [Google Scholar]
  2. FengY. SpeziaM. HuangS. YuanC. ZengZ. ZhangL. JiX. LiuW. HuangB. LuoW. LiuB. LeiY. DuS. VuppalapatiA. LuuH.H. HaydonR.C. HeT.C. RenG. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.Genes Dis.2018527710610.1016/j.gendis.2018.05.00130258937
     [Google Scholar]
  3. RussnesH.G. LingjærdeO.C. Børresen-DaleA.L. CaldasC. Breast cancer molecular stratification.Am. J. Pathol.2017187102152216210.1016/j.ajpath.2017.04.02228733194
     [Google Scholar]
  4. JungY JeongSK KangDK MoonY KimTH Quantitative analysis of background parenchymal enhancement in whole breast on MRI: Influence of menstrual cycle and comparison with a qualitative analysis.Eur. J. Radiol.2018103848910.1016/j.ejrad.2018.04.009
     [Google Scholar]
  5. JohanssonALV TrewinCB FredrikssonI ReinertsenKV RussnesH UrsinG In modern times, how important are breast cancer stage, grade and receptor subtype for survival: A population-based cohort study.Breast Cancer Res.2021231710.1186/s13058‑021‑01393‑z
     [Google Scholar]
  6. ArasuV.A. MigliorettiD.L. SpragueB.L. AlsheikN.H. BuistD.S.M. HendersonL.M. HerschornS.D. LeeJ.M. OnegaT. RauscherG.H. WernliK.J. LehmanC.D. KerlikowskeK. Population-based assessment of the association between magnetic resonance imaging background parenchymal enhancement and future primary breast cancer risk.J. Clin. Oncol.2019371295496310.1200/JCO.18.0037830625040
     [Google Scholar]
  7. KimJ.Y. KimS.H. KimY.J. KangB.J. AnY.Y. LeeA.W. SongB.J. ParkY.S. LeeH.B. Enhancement parameters on dynamic contrast enhanced breast MRI: Do they correlate with prognostic factors and subtypes of breast cancers?Magn. Reson. Imaging2015331728010.1016/j.mri.2014.08.03425179138
     [Google Scholar]
  8. TeixeiraS.R.C. Camargo JúniorH.S.A. CabelloC. Background parenchymal enhancement: Behavior during neoadjuvant chemotherapy for breast cancer and relationship with a pathological complete response.Radiol. Bras.20205329510410.1590/0100‑3984.2019.005732336824
     [Google Scholar]
  9. van der VeldenB.H.M. EliasS.G. BismeijerT. LooC.E. ViergeverM.A. WesselsL.F.A. GilhuijsK.G.A. Complementary value of contralateral parenchymal enhancement on DCE-MRI to prognostic models and molecular assays in high-risk ER+/HER2− breast cancer.Clin. Cancer Res.201723216505651510.1158/1078‑0432.CCR‑17‑017628790119
     [Google Scholar]
  10. LiJ. MoY. HeB. GaoQ. LuoC. PengC. ZhaoW. MaY. YangY. Association between MRI background parenchymal enhancement and lymphovascular invasion and estrogen receptor status in invasive breast cancer.Br. J. Radiol.20199211032019041710.1259/bjr.2019041731398071
     [Google Scholar]
  11. RellaR. ContegiacomoA. BufiE. MercoglianoS. BelliP. ManfrediR. Background parenchymal enhancement and breast cancer: A review of the emerging evidences about its potential use as imaging biomarker.Br. J. Radiol.20219411192020063010.1259/bjr.2020063033035073
     [Google Scholar]
  12. HaR. MangoV. Al-KhaliliR. MemaE. FriedlanderL. DesperitoE. WynnR.T. Evaluation of association between degree of background parenchymal enhancement on MRI and breast cancer subtype.Clin. Imaging20185130731010.1016/j.clinimag.2018.05.00829945057
     [Google Scholar]
  13. MercadoC.L. BI-RADS update.Radiol. Clin. North Am.201452348148710.1016/j.rcl.2014.02.00824792650
     [Google Scholar]
  14. MannR.M. PinkerK. Is background parenchymal enhancement an important risk factor for breast cancer development in women with increased risk?Radiology2019292356256310.1148/radiol.201919116431237810
     [Google Scholar]
  15. MemaE. SchnabelF. ChunJ. KaplowitzE. PriceA. GoodgalJ. MoyL. The relationship of breast density in mammography and magnetic resonance imaging in women with triple negative breast cancer.Eur. J. Radiol.202012410881310.1016/j.ejrad.2020.10881331927471
     [Google Scholar]
  16. HaR. ChangP. MemaE. MutasaS. KarcichJ. WynnR.T. LiuM.Z. JambawalikarS. Fully automated convolutional neural network method for quantification of breast MRI fibroglandular tissue and background parenchymal enhancement.J. Digit. Imaging201932114114710.1007/s10278‑018‑0114‑730076489
     [Google Scholar]
  17. DilorenzoG. TelegrafoM. La ForgiaD. Stabile IanoraA.A. MoschettaM. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.Eur. J. Radiol.201911314815210.1016/j.ejrad.2019.02.01830927939
     [Google Scholar]
  18. LiaoGJ Henze BancroftLC StrigelRM ChitaliaRD KontosD MoyL Background parenchymal enhancement on breast MRI: A comprehensive review.J. Magn. Reson. Imaging2020511436110.1002/jmri.26762
     [Google Scholar]
  19. TelegrafoM. RellaL. Stabile IanoraA.A. AngelelliG. MoschettaM. Breast MRI background parenchymal enhancement (BPE) correlates with the risk of breast cancer.Magn. Reson. Imaging201634217317610.1016/j.mri.2015.10.01426597834
     [Google Scholar]
  20. ÖztürkM. PolatA.V. SüllüY. TomakL. PolatA.K. Background parenchymal enhancement and fibroglandular tissue proportion on breast MRI: Correlation with hormone receptor expression and molecular subtypes of breast cancer.J. Breast Health2017131273310.5152/tjbh.2016.324728331765
     [Google Scholar]
  21. MurakamiW. MortazaviS. YuT. Kathuria-PrakashN. YanR. FischerC. McCannK.E. Lee-FelkerS. SungK. Clinical significance of background parenchymal enhancement in breast cancer risk stratification.J. Magn. Reson. Imaging20245951742175710.1002/jmri.2901537724902
     [Google Scholar]
  22. ArefanD. ZuleyM.L. BergW.A. YangL. SumkinJ.H. WuS. Assessment of background parenchymal enhancement at dynamic contrast-enhanced MRI in predicting breast cancer recurrence risk.Radiology20243101e23026910.1148/radiol.23026938259203
     [Google Scholar]
/content/journals/cmir/10.2174/0115734056347327250117073638
Loading
Background Parenchymal Enhancement in Breast MRI Correlates with Molecular Subtypes of Breast Cancer
Curr. Med. Imaging 21, E15734056347327 (2025); https://doi.org/10.2174/0115734056347327250117073638
/content/journals/cmir/10.2174/0115734056347327250117073638
/content/journals/cmir/10.2174/0115734056347327250117073638
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Background parenchymal enhancement; Breast cancer; Dynamic enhancement; Fibroglandular Tissue (FGT); Magnetic resonance imaging; Molecular subtype

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test